INTRODUCTION
============

Deregulation of proper transcriptional and translational control triggers tumorigenesis. Several multifunctional proteins are involved in both transcriptional and translational control ([@B58]). Here we focus on a family of such multifunctional proteins, the Y-box protein family, in terms of its significance in cell proliferation and cancer. As different aspects of the Y-box proteins have already been reviewed ([@B35]; [@B53]; [@B11]; [@B29]), we briefly appraise the structure and functions of the Y-box proteins with the emphasis on recent findings. We then summarize the role of a Y-box protein YB-1 in cancer and its use in the clinical setting.

Y-box proteins (or Y-box binding proteins) are so named because they were originally identified as DNA binding proteins that are capable of associating with the Y-box (inverted CCAAT-box) sequence of the major histocompatibility complex class II gene. Y-box proteins have thus far been known to regulate positively or negatively a number of genes, such as multidrug resistance 1, cyclin A, cyclin B1, matrix metalloproteinase 2 and collagen alpha2(I) ([@B19]; [@B27]; [@B29]). However, members of Y-box protein family are also found in the cytoplasm and associated with mRNAs as major components of messenger ribonucleoprotein particles. Y-box proteins regulate translation in a dose-dependent manner; low concentrations of Y-box proteins activate translation and high concentrations repress it ([@B11]). Collectively, Y-box proteins have been implicated in the regulation of mRNA metabolism in multiple steps in both the nucleus and the cytoplasm, including transcription, splicing, mRNA stability and translation.

Structure and cellular localization of Y-box proteins
-----------------------------------------------------

Y-box proteins consist of three domains: the N-terminal domain, the cold shock domain (CSD) and the C-terminal tail domain ([Figure 1](#F1){ref-type="fig"}). The CSD is a highly conserved nucleic acid binding domain that confers RNA- and single-stranded and double-stranded DNA binding activities to the Y-box proteins. Both the short N-terminal and the C-terminal tail domains are less conserved among the Y-box proteins. The charged C-terminal tail domain of vertebrate Y-box proteins, consisting of alternating clusters of acidic/aromatic and basic amino acids, is likely to account for its RNA-binding activity and ability for associating with various proteins. Y-box proteins have been shown to interact with a number of cellular and viral proteins that are involved in various cellular processes ([Figure 2](#F2){ref-type="fig"}).

![Schematic diagram depicting the structure of the Y-box protein. ++ and − − indicate clusters of basic and acidic/aromatic amino acids. Functions attributed to each domain are summarized at the bottom.](jmgm-01-011-g001){#F1}

![Cellular and viral proteins that interact with the Y-box protein. Numbers in parentheses indicate the references as follows: (1) [@B50], (2) [@B29]; [@B53] and references therein, (3) [@B20], (4) [@B45], (5) [@B64], (6) [@B30], (7) [@B9], (8) [@B39], (9) [@B14], (10) [@B44], (11) [@B57], (12) [@B36], (13) [@B5], (14) [@B38], (15) [@B35]; [@B11] and references therein, (16) [@B4], (17) [@B12].](jmgm-01-011-g002){#F2}

In a variety of cell types, Y-box proteins are predominantly found in the cytoplasm. However, given that Y-box proteins regulate transcription, they are expected to localize to the nucleus. Y-box proteins are translocated into the nucleus by a number of conditions and mechanisms, including UV irradiation, hyperthermia, interferon-gamma treatment, adenovirus infection, interaction with p53 and a splicing factor SRp30c and high levels of ectopic YB-1expression ([@B19]; [@B29]; [@B44] and references therein; [@B62]). Both the CSD and the tail domains are implicated in nuclear localization of YB-1; the tail domain seems to contain a non-canonical nuclear localization signal and the isolated CSD also contributes to nuclear retention ([@B2]). Y-box proteins are capable of nucleocytoplasmic shuttling, which allows them to contribute to the coupling control of transcription and translation. Y-box proteins become associated with nascent transcripts cotranscriptionally and are presumed to accompany mRNA into the cytoplasm ([@B52]). Interestingly, a mouse Y-box protein MSY2 preferentially associates with mRNAs that are transcribed from genes containing Y-box sequences in their promoter regions and stores those mRNAs in male germ cells ([@B60]).

Regulation of the synthesis of Y-box proteins
---------------------------------------------

Experiments with overexpression or down-regulation of the Y-box proteins in cultured cells or animals have shown that the amount of Y-box proteins must be precisely controlled (see below). Therefore, it is important to understand how the synthesis of Y-box proteins is regulated. Recent data have shown that the synthesis of a Y-box protein, YB-1 (Y-box binding protein-1), is regulated both at transcriptional and post-transcriptional levels. YB-1 mRNA accumulates when cells are treated with cisplatin or UV irradiation ([@B42]). Transcription of the YB-1 gene is stimulated by p73 through an enhanced recruitment of the c-Myc-Max complexes to E-box sequences in the YB-1 promoter ([@B56]). Once synthesized, YB-1 mRNA is negatively regulated by its own product. YB-1 protein represses translation of YB-1 mRNA by binding to specific elements in the 5′- and 3′-untranslated regions ([@B13]; [@B51]). This self-regulation may contribute towards maintaining the concentration of YB-1 protein optimal in a cell.

Physiological functions of Y-box proteins
-----------------------------------------

In human and mouse, there are three Y-box proteins, two of which are expressed in both somatic cells and germ cells ([Table 1](#T1){ref-type="table"}). The most extensively studied Y-box protein, YB-1, is ubiquitously expressed in various tissues. Human Contrin and mouse MSY2 are germ cell-specific members of the Y-box protein family. Analyses of the effects of targeting Y-box genes in chicken cells and mice have been widely carried out in the last three years. Chicken B-cell lymphoma DT40 cells are widely used to study functional consequences of disrupting specific genes because of the high frequency of homologous recombination. The YB-1 (or YB-1b) gene in DT40 cells has been disrupted by two independent groups of investigators; one group reported that YB-1^+/−^ cells show slow-growth phenotype and increased DNA content ([@B54]). The other group of researchers found that heterozygous disruption resulted in no growth defects but homozygous gene disruptants exhibited a slow and cold-sensitive growth phenotype ([@B36]). One research group tried to disrupt YB-1 gene in mice but encountered difficulties in disrupting both alleles of the YB-1 gene ([@B48]). They found hypersensitivity of the YB-1^+/−^ cells to genotoxic stresses. However, as was the case in chicken cells, another group recently reported homozygous YB-1gene disruption, showing the importance of YB-1 in late stages of embryonic development ([@B34]). They observed developmental defects of YB-1^−/−^embryos after embryonic day 13.5 including craniofacial lesions, hemorrhage and respiratory failure, with YB-1^−/−^ MEF cells showing premature senescence and hypersensitivity to different cellular stresses. The reason for the presence or absence of the haplo-insufficient phenotypes is currently unknown. In mice lacking MSY2, both male and female homozygotes are sterile, a consequence of disturbed spermatogenesis due to reduction of postmeiotic germ-cell mRNAs in male and oocyte loss in female ([@B61]). Overall, studies designed to reduce or deplete a Y-box protein in cells or whole organisms underscore the significance of Y-box proteins in appropriate cell growth, stress responses and development.

###### 

Y-box proteins in human and mouse

  Human       Mouse       Expression                                          Phenotype in knockout mice
  ----------- ----------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  YB-1/DbpB   YB-1/MSY1   Ubiquitous                                          Embryonic/perinatal lethality (neurological abnormalities, haemorrhage, respiratory failure and growth retardation)[\*](#TF1_1){ref-type="table-fn"}
  DbpA        MSY4        Ubiquitous (abundant in heart, muscle and testis)   Unknown
  Contrin     MSY2        Germ cells                                          Male and female infertility[\*\*](#TF1_2){ref-type="table-fn"}

[@B34]

[@B61]

Role of YB-1 in tumorigenesis
-----------------------------

The role of YB-1 in cancer progression has attracted attention in recent years.YB-1 has been found to be upregulated during prostate cancer tumor progression ([@B16]). Increased YB-1 expression has been correlated with DNA topoisomerase IIα and proliferating cell nuclear antigen expression in human lung cancer ([@B18]) and colorectal cancer ([@B49]) and linked to markers of cellular proliferation in osteosarcoma ([@B40]). YB-1 has been identified as a cell cycle stage-specific transcription factor ([@B27]). Nuclear accumulation of YB-1 in HeLa cells was demonstrated to transcriptionally activate cyclin A and B1 genes, which are crucial for cell cycle progression. Increase in cyclin A has been reported to be associated with poor clinical outcome in breast cancer ([@B37]).

In addition, YB-1 is believed to promote metastasis by enhancing the transcription of gelatinase A, a matrix metalloproteinase that facilitates cell migration ([@B10]). Recently, [@B8] has also shown that YB-1 may induce epidermal growth factor (EGF) independence in mammary epithelial cells via activation of the EGF receptor pathway, thereby contributing to breast tumor aggressiveness. In yet another recent paper, [@B7], using a transgenic mouse model, showed that overexpression of YB-1 may cause breast cancer through the induction of genetic instability.

On the other hand, YB-1 may have anti-oncogenic activity as it is reported to be capable of blocking oncogenic cell transformation ([@B2]). The phosphoinositide 3-kinase (PI 3-kinase) pathway is known to show gain of function in human cancers ([@B1]). The catalytic subunits of PI 3-Kinase, p110 (of which P3K is a homolog) and Akt are oncoproteins and YB-1 is specifically known to inhibit P3K and Akt-induced transformation involving protein synthesis ([@B3]). YB-1 may interefere with the synthesis of growth-related proteins including growth factors, receptors, kinases, transcriptional regulators and cell cycle proteins associated with P3K and Akt pathways ([@B63]; [@B1]).

A seminal paper describing YB-1 expression in cancer tissues was first reported by Royer\'s group in breast cancer ([@B6]). The pathological significance of YB-1 in a variety of cancers is shown in [Table 2](#T2){ref-type="table"}.

###### 

Overexpression of YB-1 and pathological significance in human cancers

  Organ             Tumors                                                                                     Pathological Significance                                                                     Reference
  ----------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------- -----------
  Breast            Invasive ductal breast cancer                                                              Tumor aggressiveness and axillary lymph node positivity                                       [@B23]
                                                                                                               Associated with progesterone receptor positivity but no prognostic value                      [@B46]
                    Breast cancer (histologic subtype not specified)                                           Higher risk for relapse without postoperative chemotherapy                                    [@B26]
  Ovary             Surface epithelial neoplasms (serous, mucinous, endometroid & clear cell)                  Co-expression with P-glycoprotein associated with poor survival                               [@B22]
                    Surface epithelial neoplasms (mainly serous)                                               Higher nuclear expression in recurrent lesions than in primary tumors                         [@B59]
                    Serous adenocarcinoma                                                                      Poor prognosis                                                                                [@B28]
  Lung              Nonsmall cell lung cancer                                                                  Nuclear expression correlated with reduced survival                                           [@B15]
                                                                                                               Nuclear expression correlated with node metastasis, stage of the disease and poor prognosis   [@B47]
                    Squamous cell carcinoma                                                                    Poor prognosis                                                                                [@B47]
                    Adenocarcinoma                                                                             Associated with T3-4 and Stage II-IV tumors                                                   [@B18]
  Thyroid           Anaplastic (undifferentiated) carcinomas, papillary carcinomas and follicular carcinomas   High expression in anaplastic carcinoma (known to be rapidly progressive)                     [@B25]
  Soft tissues      Synovial sarcoma                                                                           Poor prognosis                                                                                [@B41]
  Large intestine   Colorectal adenocarcinoma                                                                  Proliferation associated marker                                                               [@B49]

YB-1 and chemoresistance in human tumors
----------------------------------------

Substantial YB-1 expression was demonstrated in multidrug-resistant breast, gastric and pancreatic cell lines ([@B21]). Altered drug sensitivity to cisplatin, a very potent and widely used anti-cancer agent and mitomycin C has been observed following treatment of cells with antisense YB-1 ([@B42]; [@B55]). Expression of YB- 1 protein has been reported to reflect the chemosensitivity of ovarian serous adenocarcinoma ([@B28]) and breast cancer ([@B26]; [@B23]). Increased nuclear localization of YB-1 has been observed in acquired cisplatin-resistant ovarian cancer ([@B59]).

YB-1 expression has also been shown to be associated with P-glycoprotein (Pgp) expression in breast cancer cells resulting in drug resistance ([@B6]; [@B46]; [@B23]). Pgp, encoded by the MDR1 gene, is a member of the ATP-binding cassette transporter superfamily of proteins involved in the protection of cells from xenobiotics and drugs ([@B32]). Pgp has become an important molecular target for limiting chemoresistance as it plays a major role in the development of multidrug-resistant tumor type and is known to mediate resistance to a wide range of anticancer agents ([@B31]). Bay and co-workers have recently demonstrated a direct interaction between YB-1 and Pgp using the computer-based Resonance Recognition Model ([@B23]). The same investigators observed the occurrence of raised recurrence rates in breast tumor patients with high YB-1 expression who underwent a chemotherapy regime which contained anthracycline (a Pgp substrate). Besides breast cancer, YB-1 has been correlated with Pgp in ovarian cancer ([@B22]), prostate cancer ([@B16]) and osteosarcoma ([@B40]).

YB-1 has been shown to bind p53 ([@B43]) and interaction with p53 could be necessary for the self-defense of cells exposed to DNA-damaging agents ([@B32]). As mentioned earlier, p73, a close relative of the p53 family, has also been observed to stimulate transcription of the YB-1 promoter by enhancing the recruitment of the cMyc-Max complex to its target gene ([@B56]). c-Myc, an oncogene with a dual function in cell proliferation and apoptosis can confer resistance to cisplatin. p73 is known to induce apoptosis ([@B24]). and p73 overexpressing clones have been observed to be cisplatin resistant ([@B17]). Hence, c-Myc and p73 may form a complex necessary in YB-1 mediated drug resistance ([@B56]).

CONCLUSIONS
===========

Expression of the YB-1 protein has a prognostic significance in determining disease progression in human cancers. Perhaps more importantly, YB-1 has the potential to be a biological marker which predicts chemotherapy resistance and aid in the selection of appropriate adjuvant chemotherapy. There has been cumulative evidence in the literature to suggest that YB-1 is involved in pleiotropic resistance to different classes of DNA-targeting drugs ([@B33]). As clinical drug resistance hampers effective chemotherapy, a recent focus in cancer therapeutic strategy is to develop molecular cancer therapeutics ([@B32]; [@B21]). In this regard, YB-1 holds promise as target molecule for the development of novel approaches in overcoming multidrug resistance in cancer chemotherapy ([@B26]).
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